Implementation uptake and commissioned reports

NICE produces implementation uptake reports to assess the level of compliance with guidance across the NHS. NICE has also previously commissioned a number of external reports and surveys on the uptake of guidance.

Implementation uptake reports are based on the analysis of data that is available at a national level from a number of sources including:

• ePACT: the Prescribing Analysis and Cost Tool system which covers primary care prescriptions in England
• FP10(HP): information covering prescriptions written in hospitals intended for dispensing in the community
• IMS HPAI: the IMS Health Hospital Pharmacy Audit Index (IMS HPAI) database which covers issues of medicines recorded on hospital pharmacy systems in the UK.
• IMS disease analyser: collects data from a sample of GP practice systems. Around 130 are currently delivering data and the database has around 2.6 million patient records, 1.1 million of which are currently registered.
• HES: the Hospital Episodes Statistics national data warehouse provides a range of information on the care provided by NHS hospitals in England and for NHS hospital patients treated elsewhere.

Some of these data sources are accessed in-house and others via the NHS Information Centre. Details of the methods used are included in each implementation uptake report. Each report aims to examine trends in the use of a drug, procedure or technology recommended in NICE guidance. In some cases additional analysis is presented that estimates the uptake in line with assumptions based on NICE recommendations.

The extent of the reports is limited by the data available. These limitations vary depending on the information available and the guidance under consideration. The limitations and data sources are detailed in each report.

Uptake reports

The following uptake reports are sorted by topic area:

Blood and immune system

• None

Cancer

• Capecitabine and oxaliplatin in the adjuvant treatment of stage III colon cancer (TA100)
• Laparoscopic surgery for colorectal cancer (TA105)
• The diagnosis and treatment of lung cancer (CG24)

Cardiovascular

• Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome
• Hypertension - management of hypertension in primary care
• Myocardial infarction (MI) - secondary prevention (CG48)
• Statins for the prevention of cardiovascular events (TA94)

Central nervous system

• Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111)
• Epilepsy - the diagnosis and management of the epilepsies in adults and children in primary and secondary care (CG20)
• Riluzole (TA20)

Diagnostic procedures

• None

Digestive system

• Adefovir dipivoxil to treat hepatitis B (TA96)
• Capecitabine and oxaliplatin in the adjuvant treatment of stage III colon cancer (TA100)
• Drugs used to treat hepatitis C (TA75)
• Laparoscopic surgery for colorectal cancer (TA105)
• Laparoscopic surgery for inguinal hernia repair (TA83)

Ear and nose

• None

Endocrine, nutritional and metabolic

• Diabetes - glitazones (rosiglitazone and pioglitazone) (CG66)
• Diabetes (types 1 and 2) - insulin glargine (TA53 and CG66)
• Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolemia (TA132)
• Surgical and pharmacological interventions for obesity (CG43)

Eye

• None

Gynaecology, pregnancy and birth

• Heavy menstrual bleeding (CG44)
• Long acting reversible contraception (CG30)

Infectious diseases

• Adefovir dipivoxil to treat hepatitis B (TA96)
• Drotrecogin alfa (activated) for severe sepsis (TA84)
• Drugs used to treat hepatitis C (TA75)

Injuries, accidents and wounds

• Triage, assessment, investigation and early management of head injury in infants, children and adults (CG56)

Mental health and behavioural conditions

• Anxiety (CG22)
• Attention deficit hyperactivity disorder (ADHD), management of ADHD in children, young people and adults (CG72)
• Atypical antipsychotics (TA43)
• Bipolar disorder (CG38)
• Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111)
• Newer hypnotic drugs for insomnia (TA77)

Mouth and dental

• None

Musculoskeletal

• Cox II selective inhibitors (TA27)
• Management of rheumatoid arthritis in adults (CG79)

Public health

• Anxiety (CG22)
• Attention deficit hyperactivity disorder (ADHD), management of ADHD in children, young people and adults (CG72)
• Long acting reversible contraception (CG30)
• Myocardial infarction (MI) - secondary prevention (CG48)
• Nicotine replacement therapy (NRT), bupropion and varenicline for smoking cessation (TA123)
• Surgical and pharmacological interventions for obesity (CG43)

Respiratory

• Omalizumab for severe persistent allergic asthma (TA133)

Skin

• Pimecrolimus and tacrolimus for atopic eczema (TA82)

Surgical procedures

• Laparoscopic surgery for colorectal cancer (TA105)
• Laparoscopic surgery for inguinal hernia repair (TA83)
• Obesity - surgical interventions (CG43)

Therapeutic procedures

• None

Urogenital

• Drugs used in the management of urinary incontinence (CG40)

Commissioned surveys and reports

• Commissioned surveys and reports